Transgene Statistics

Total Valuation

Transgene has a market cap or net worth of EUR 170.76 million. The enterprise value is 185.06 million.

Market Cap	170.76M
Enterprise Value	185.06M

Important Dates

The next estimated earnings date is Tuesday, November 4, 2025.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Transgene has 132.38 million shares outstanding. The number of shares has increased by 30.91% in one year.

Current Share Class	132.38M
Shares Outstanding	132.38M
Shares Change (YoY)	+30.91%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	69.64%
Owned by Institutions (%)	0.05%
Float	35.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.54
PB Ratio	-47.38
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.03
EV / Sales	24.43
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.62

Financial Position

The company has a current ratio of 0.54

Current Ratio	0.54
Quick Ratio	0.46
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.28
Interest Coverage	-17.59

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-49.35%
Return on Invested Capital (ROIC)	-71.16%
Return on Capital Employed (ROCE)	-4,406.33%
Revenue Per Employee	51,531
Profits Per Employee	-250,211
Employee Count	144
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +27.72% in the last 52 weeks. The beta is 0.78, so Transgene's price volatility has been lower than the market average.

Beta (5Y)	0.78
52-Week Price Change	+27.72%
50-Day Moving Average	1.13
200-Day Moving Average	0.84
Relative Strength Index (RSI)	64.98
Average Volume (20 Days)	131,644

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Transgene had revenue of EUR 7.58 million and -36.78 million in losses. Loss per share was -0.28.

Revenue	7.58M
Gross Profit	-29.19M
Operating Income	-36.22M
Pretax Income	-36.78M
Net Income	-36.78M
EBITDA	-34.90M
EBIT	-36.22M
Loss Per Share	-0.28

Full Income Statement

Balance Sheet

The company has 16.77 million in cash and 31.07 million in debt, giving a net cash position of -14.29 million or -0.11 per share.

Cash & Cash Equivalents	16.77M
Total Debt	31.07M
Net Cash	-14.29M
Net Cash Per Share	-0.11
Equity (Book Value)	-3.60M
Book Value Per Share	-0.03
Working Capital	-18.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -22.96 million and capital expenditures -1.34 million, giving a free cash flow of -24.30 million.

Operating Cash Flow	-22.96M
Capital Expenditures	-1.34M
Free Cash Flow	-24.30M
FCF Per Share	-0.18

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-478.15%
Pretax Margin	-485.56%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Transgene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.91%
Shareholder Yield	-30.91%
Earnings Yield	-21.54%
FCF Yield	-14.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Transgene has an Altman Z-Score of -3.81 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.81
Piotroski F-Score	4